NSE ScannerPharmaceuticals · Pharmaceuticals: Other · NSE: SUDEEPPHRM · data 2026-11-01
Sudeep Pharma Limited
In plain words
Price: 22.5% below its 52-week high of ₹1,378.
Delivery: 45.7% of traded shares were kept for delivery over the last 10 sessions, against 48.6% over the last 60.
Latest results: a net profit of ₹52 cr for the quarter ended Sept 2026 (+13.2% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹710 cr |
| Net profit (last 12 months) | ₹188 cr |
| Sales growth, 3 years (yearly) | 14.4% |
| Profit growth, 3 years (yearly) | 40.5% |
At a glance
Promoters 76.2%, pledged 0.0%, institutions 17.0%.
P/E 64.1, P/B 12.6, dividend yield 0.1%. Price relative to earnings and book value (low is cheaper, not better).
ROE 25.1%, ROCE 28.4%, operating margin 32.9%: how much profit it earns on the money it uses.
Debt/equity 0.17, Profit growth 40.5% and sales growth 14.4% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- High return on equity (25.1%).
- Healthy operating margin (32.9%).
- Profit grew 40.5% a year over 3 years.
- Expensive on earnings (P/E 64.1).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY27)
SUDEEPPHRM Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹196.7 crore, up 20.9% YoY and up 24.3% QoQ.
Net profit was ₹51.81 crore, up 13.2% YoY and up 27.8% QoQ.
Operating margin was 37.2% (34.1% a year ago).
EPS was ₹4.59, up 9.3% YoY and up 27.9% QoQ.
SUDEEPPHRM के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹196.7 करोड़; पिछले साल की तुलना में 20.9% की बढ़त, पिछली तिमाही की तुलना में 24.3% की बढ़त।
शुद्ध मुनाफ़ा: ₹51.81 करोड़; पिछले साल की तुलना में 13.2% की बढ़त, पिछली तिमाही की तुलना में 27.8% की बढ़त।
ऑपरेटिंग मार्जिन: 37.2% (एक साल पहले 34.1%)।
EPS: ₹4.59; पिछले साल की तुलना में 9.3% की बढ़त, पिछली तिमाही की तुलना में 27.9% की बढ़त।
SUDEEPPHRMના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹196.7 કરોડ; ગયા વર્ષની સરખામણીએ 20.9% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 24.3% વધારો.
ચોખ્ખો નફો: ₹51.81 કરોડ; ગયા વર્ષની સરખામણીએ 13.2% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 27.8% વધારો.
ઓપરેટિંગ માર્જિન: 37.2% (એક વર્ષ પહેલાં 34.1%).
EPS: ₹4.59; ગયા વર્ષની સરખામણીએ 9.3% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 27.9% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
24/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 4/30: Delivery 46.2% over the last 20 sessions vs 44.3% in the 40 before (1.04x); shares delivered per day 1.01x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 7/15: 8 schemes hold it, about ₹431 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 8/15: Verdict "Building", sustained score 56/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Insider ● Dividend
- 28 Oct 26Results Q2 FY27 results: profit +13.2% YoY +10.5% next session
- 4 Aug 26Results Q1 FY27 results: net profit ₹40.5 cr +10.5% next session
- 29 Jul 26Insider SAST disclosure: Nuvama Crossover Opportunites Fund-… acquired shares -0.6% next session
- 23 Jul 26Dividend Dividend ₹1.5 (ex-date) -2.9% next session
- 25 Jun 26Results Q4 FY26 results: net profit ₹48.9 cr -3.5% next session
- 6 Feb 26Results Q3 FY26 results: net profit ₹47.6 cr +6.7% next session
- 19 Dec 25Results Q2 FY26 results: net profit ₹45.8 cr -1.4% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹197 cr | ₹52 cr | +13.2% | 37.2% | 4.59 |
| Jun 2026 | ₹158 cr | ₹41 cr | — | 34.7% | 3.59 |
| Mar 2026 | ₹182 cr | ₹49 cr | — | 34.3% | 4.38 |
| Dec 2025 | ₹172 cr | ₹48 cr | — | 34.8% | 4.29 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 76.15% | 76.15% | 76.15% | 76.15% |
| Foreign institutions (FII) | 2.93% | 1.81% | 1.55% | 1.67% |
| Domestic institutions (DII) | 14.05% | 15.65% | 18.11% | 17.60% |
| Mutual funds | 7.43% | 5.47% | 6.19% | 5.67% |
| Retail investors | 4.10% | 3.56% | 1.78% | 1.94% |
| Number of shareholders | 40,465 | 35,695 | 36,503 | 43,599 |
Common questions
What was Sudeep Pharma Limited's latest quarterly profit?
Sudeep Pharma Limited reported a net profit of ₹52 cr for the quarter ended Sept 2026 (+13.2% on the same quarter a year earlier), on revenue of ₹197 cr.
How much do promoters hold in Sudeep Pharma Limited?
Promoters held 76.15% of Sudeep Pharma Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Sudeep Pharma Limited debt-free?
Its latest reported debt-to-equity ratio is 0.17.
What is Sudeep Pharma Limited's P/E ratio?
About 64.1, based on the last 12 months' earnings and a price of ₹1,068.3 (data 2026-11-01).
What is the 52-week high and low of Sudeep Pharma Limited?
The 52-week high is ₹1,378 and the 52-week low is ₹524.05.
Mutual funds holding Sudeep Pharma Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 8 schemes holding about ₹431 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 2.79% | ₹164 cr |
| SBI Comma Fund | SBI Mutual Fund | 6.86% | ₹83 cr |
| SBI MNC Fund | SBI Mutual Fund | 1.30% | ₹83 cr |
| ADITYA BIRLA SUN LIFE SMALL CAP FUND | Aditya Birla Sun Life Mutual Fund | 0.71% | ₹43 cr |
| SBI RETIREMENT BENEFIT FUND - AGGRESSIVE PLAN | SBI Mutual Fund | 1.29% | ₹40 cr |
| SBI RETIREMENT BENEFIT FUND - AGGRESSIVE HYBRID PLAN | SBI Mutual Fund | 1.07% | ₹17 cr |
| SBI RETIREMENT BENEFIT FUND - CONSERVATIVE HYBRID PLAN | SBI Mutual Fund | 0.51% | ₹1 cr |
| SBI RETIREMENT BENEFIT FUND - CONSERVATIVE PLAN | SBI Mutual Fund | 0.25% | ₹0 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Sudeep Pharma Limited | ₹1,068.3 | ₹12,048 cr | 64.1 | 12.6 | 25.1% | 28.4% | 0.17 | +46.3% |
| Cipla Ltd | ₹1,378.9 | ₹1,11,486 cr | 38.5 | 3.2 | 11.8% | 14.5% | 0.02 | -13.1% |
| Aurobindo Pharma Ltd | ₹1,681.4 | ₹96,537 cr | 26.3 | — | 9.9% | 15.1% | 0.21 | +51.1% |
| Lupin Limited | ₹2,011 | ₹91,870 cr | 16.7 | — | 26.9% | 30.7% | 0.3 | +2.8% |
| Granules India Limited | ₹839.75 | ₹20,804 cr | 31.2 | — | 13.5% | 17.9% | 0.3 | +46.8% |
| Amrutanjan Health Care Limited | ₹496.65 | ₹1,452 cr | 26.6 | — | 16.6% | 17.9% | 0 | -33.0% |
Compare SUDEEPPHRM with CIPLA in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SUDEEPPHRM in NSE Scanner →